Nykode Therapeutics As (VACBF) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nykode Therapeutics Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.178 -- 00:00:06.226 Greetings, and welcome to the NICO Therapeutics Q1 2025 Financial Results 00:00:06.226 -- 00:00:11.435 Presentation. At this time, all participants are in listen-only mode. 00:00:11.435 -- 00:00:15.081 If anyone would require operator assistance, please press star zero on your telephone 00:00:15.081 -- 00:00:19.328 keypad. A question and answer session will follow the formal presentation. 00:00:19.328 -- 00:00:24.016 You may ask a question at any time by typing it into the Ask a Question feature on your 00:00:24.016 -- 00:00:27.892 screen. As a reminder, this conference is being recorded. 00:00:27.892 -- 00:00:32.316 It's now my pleasure to introduce our host, Michael Ensig, CEO of Nyco Therapeutics. 00:00:32.316 -- 00:00:34.618 Please go ahead, Michael. 00:00:34.618 -- 00:00:39.703 Thank you very much, Kevin. And also from my side, a very warm welcome 00:00:39.703 -- 00:00:45.088 to all participants to this webcast for our first quarter results 00:00:45.088 -- 00:00:50.433 and updates from the business. A quick reminder of our forward-looking statements. 00:00:50.433 -- 00:00:54.537 Assuming you're all familiar with this kind of forward-looking statements, we will move 00:00:54.537 -- 00:00:59.689 on. As usual, I am very happy to have with me here 00:00:59.689 -- 00:01:04.755 today, André Frederiksen, our Chief Scientific Officer and Head of Business Development 00:01:04.755 -- 00:01:06.536 and Co-Founder, 00:01:06.536 -- 00:01:09.720 as well as Hal Guren, our Chief Financial Officer. 00:01:09.720 -- 00:01:15.165 And together we'll try to take you through a deep dive in the business update 00:01:15.165 -- 00:01:19.408 and the financial numbers for the first quarter. 00:01:20.791 -- 00:01:25.999 So, happy to report that we have fin...